LifeSignals無線醫療生物感測器LP1250獲得FDA批准

By PR Newswire on 22 Jul 2020

PR Newswire (www.prnasia.com), a Cision company, is the premier global provider of media monitoring platforms and news distribution services that marketers, corporate communicators and investor relations professionals leverage to engage key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, distribute, target and measure text and multimedia content across traditional, digital, mobile and social channels. Combining the world's largest multi-channel content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions.

全球首款一次性雙通道心電圖和心率生物感測器，能夠在流動、醫院和家庭背景中，進行72小時病人監測，並能進行遠程數據瀏覽

加州弗里蒙特2020年7月22日 /美通社/ -- LifeSignals集團今天宣佈，該集團的LifeSignals貼身心電圖遠程監測平台(LifeSignals ECG Remote Monitoring Patch Platform)，已經獲得了美國食品藥品監督管理局(FDA)的510(k)批准。LifeSignals貼身心電圖遠程監測平台是一種無線遠程監測系統，旨在被醫療專業人員用來在流動、醫院、家庭與醫療背景中，持續收集心電圖和心率監測數據。收集到的數據可以從LifeSignals無線醫療生物感測器LP1250，無線傳輸到遠程的安全伺服器，以便進行存儲和分析。

The Life Signals LP1250 Wireless Medical Biosensor provides 72-hour data capture of two-channel ECG and Heart Rate data 1A male.
The Life Signals LP1250 Wireless Medical Biosensor provides 72-hour data capture of two-channel ECG and Heart Rate data 1A male.

醫療專業人員可以借助第三方軟件，遠程獲取病人數據，從而對像房顫這樣的常見心律失常問題進行篩查和監測，支持迅速做出獨立於病人所在地點的治療決定。

LifeSignals聯合創辦人、行政總裁Surendar Magar表示：「在我們推動解開纏繞在病人監測系統周邊的線路上面，此次獲得FDA批准向前邁出了一大步。能夠互操作的生物感測器可以讓合作夥伴憑藉簡單直接、迅速加載的生態系統，獲取接入做好整合準備的多參數可穿戴式醫療設備的管道。一旦投入使用，這能夠支持遠程病人監測服務迅速擴展，專業人員可以更加迅速地做出治療決定，而病人能夠確信他們接受了由數據驅動的個性化治療。」